Menu Search
Equities

Anteris Technologies Ltd

AMEUF:PKC

Anteris Technologies Ltd

Actions
  • Price (USD)6.50
  • Today's Change0.95 / 17.12%
  • Shares traded1.50k
  • 1 Year change-50.00%
  • Beta--
Data delayed at least 15 minutes, as of Nov 18 2024 16:13 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Anteris Technologies Ltd is an Australia-based structural heart company. The Company is engaged in designing, developing, and commercializing medical devices. The Company’s lead product, DurAVR, is a transcatheter heart valve (THV) for treating aortic stenosis. DurAVR THV is made using ADAPT tissue, its patented anti-calcification tissue technology. DurAVR THV is a novel first-in-class biomimetic valve made from a single piece of native-shaped tissue. It is designed to mimic the performance of a pre-disease human aortic valve. Its balloon expandable ComASUR Delivery System provides controlled deployment and accurate placement of the DurAVR THV valve, designed to achieve precise alignment with the heart’s native commissures to achieve ideal valve positioning.

  • Revenue in AUD (TTM)7.14m
  • Net income in AUD-87.90m
  • Incorporated1999
  • Employees1.00
  • Location
    Anteris Technologies LtdTOOWONG TOWERSUITE 302, LEVEL 3, 9 SHERWOOD RDTOOWONG 4066AustraliaAUS
  • Phone+61 30055-0310
  • Fax+61 30088-0398
  • Websitehttps://anteristech.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.